Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLN501
- Development stage
- Unknown
- Lead developer
- Silence Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SLN501 is a small interfering RNA (siRNA) therapeutic developed to target and inhibit the expression of complement component C3, a central protein in the complement system involved in immune and inflammatory responses. By silencing C3 gene expression through RNA interference, SLN501 aims to reduce complement-mediated tissue damage associated with various immunological and complement-mediated disorders. The drug was developed using Silence Therapeutics' proprietary mRNAi GOLD platform, with initial development led by Silence Therapeutics and later partnered with Mallinckrodt for further clinical advancement. Its primary indication was for immunological disorders, including diseases such as C3 glomerulopathy. As of March 2024, following completion of phase I trials, Mallinckrodt decided not to pursue further development of SLN501[1][3][5].
- Other names
- SLN501SLN-501SLN 501
02
Targets
C3
Beyond the preview
Go deeper on SLN501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLN501.